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The interaction of alphaB-crystallin with mature alpha-synuclein amyloid fibrils
inhibits their elongation
Abstract
alphaB-Crystallin is a small heat-shock protein (sHsp) that is colocalized with alpha-synuclein (alphaSyn)
in Lewy bodies—the pathological hallmarks of Parkinson's disease—and is an inhibitor of alphaSyn
amyloid fibril formation in an ATP-independent manner in vitro. We have investigated the mechanism
underlying the inhibitory action of sHsps, and here we establish, by means of a variety of biophysical
techniques including immunogold labeling and nuclear magnetic resonance spectroscopy, that alphaBcrystallin interacts with alphaSyn, binding along the length of mature amyloid fibrils. By measurement of
seeded fibril elongation kinetics, both in solution and on a surface using a quartz crystal microbalance,
this binding is shown to strongly inhibit further growth of the fibrils. The binding is also demonstrated to
shift the monomer-fibril equilibrium in favor of dissociation. We believe that this mechanism, by which a
sHsp interacts with mature amyloid fibrils, could represent an additional and potentially generic means by
which at least some chaperones protect against amyloid aggregation and limit the onset of misfolding
diseases.
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The Interaction of aB-Crystallin with Mature a-Synuclein Amyloid Fibrils
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John A. Carver,†† Mark E. Welland,‡ John Christodoulou,{ Christopher M. Dobson,† and Sarah Meehan†*
†

University Chemical Laboratory, ‡Nanoscience Centre, and §Department of Physiology, Development and Neuroscience, University of
Cambridge, Cambridge, United Kingdom; {Department of Structural and Molecular Biology, University College London, London, United
Kingdom; kDepartment of Biochemistry and Molecular Biology, Monash University, Clayton, Australia; and ††School of Chemistry and Physics,
University of Adelaide, Adelaide, Australia

ABSTRACT aB-Crystallin is a small heat-shock protein (sHsp) that is colocalized with a-synuclein (aSyn) in Lewy bodies—the
pathological hallmarks of Parkinson’s disease—and is an inhibitor of aSyn amyloid ﬁbril formation in an ATP-independent
manner in vitro. We have investigated the mechanism underlying the inhibitory action of sHsps, and here we establish, by means
of a variety of biophysical techniques including immunogold labeling and nuclear magnetic resonance spectroscopy, that
aB-crystallin interacts with aSyn, binding along the length of mature amyloid ﬁbrils. By measurement of seeded ﬁbril elongation
kinetics, both in solution and on a surface using a quartz crystal microbalance, this binding is shown to strongly inhibit further
growth of the ﬁbrils. The binding is also demonstrated to shift the monomer-ﬁbril equilibrium in favor of dissociation. We believe
that this mechanism, by which a sHsp interacts with mature amyloid ﬁbrils, could represent an additional and potentially generic
means by which at least some chaperones protect against amyloid aggregation and limit the onset of misfolding diseases.

INTRODUCTION
Parkinson’s disease (PD) is a progressive neurodegenerative
movement disorder distinguished neuropathologically by the
presence of Lewy bodies and Lewy neurites—proteinaceous
cytoplasmic inclusions—in dopaminergic neurons of the
substantia nigra (1). Electron microscopy shows these inclusions to be composed of amyloid-like fibrillar material, the
major component of which is the 140-residue, intrinsically
disordered protein a-synuclein (aSyn) (2). Recombinant
aSyn has been found to form aggregates in vitro with all
the characteristics of amyloid fibrils associated with diseased
states (3). Although most cases of PD are idiopathic, a small
number of familial forms have been identified including the
A53T variant, in which aggregation is significantly accelerated relative to the wild-type (WT) (4), thus implicating
aSyn aggregation in the etiology of PD. As aSyn knockout
mice do not exhibit PD-like symptoms, it can be concluded
that PD results from a pathological gain of function (i.e.,
aggregate toxicity) rather than the loss of normal aSyn
function (5).
The aggregation mechanism itself, in common with other
amyloid systems, is a nucleated process in which there is
slow and initially unfavorable association of monomers
into a structure competent to elongate into full-length fibrils
(6). An important experimental consequence of such a nucleSubmitted August 3, 2009, and accepted for publication October 1, 2009.
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ation-polymerization mechanism is the phenomenon of seeding, in which a substoichiometric quantity of preformed
fibrils can greatly accelerate the aggregation reaction by bypassing the nucleation process. The aggregation kinetics of
seeded reactions are therefore determined only by the elongation and fragmentation rates, and, in the initial rate approximation, by the elongation rate alone (7).
aSyn aggregation may be suppressed by the molecular
chaperone Hsp70, and biophysical investigations have shown
that this inhibition occurs via binding to prefibrillar species
rather than monomeric aSyn (8). Another molecular chaperone that inhibits aSyn aggregation is aB-crystallin, a
175-residue protein ubiquitous in mammalian tissue (9).
Early work showed that aB-crystallin is a member of the
family of small heat shock proteins (sHsps), and is upregulated in response to a range of stress stimuli and clinical
disorders including Alzheimer’s disease, transmissible spongiform encephalopathies, dementia with Lewy bodies, and
Parkinson’s disease (10). As a sHsp, aB-crystallin is a molecular chaperone and has been demonstrated to suppress
thermally induced aggregation of b- and g-crystallins, suggesting that it acts as a significant protective mechanism
against cataract formation in the eye lens (11); the latter is
associated with aggregation and has been shown in some
cases to involve amyloid formation (12). aB-Crystallin
also inhibits the aggregation of several other proteins
in vitro, including the amyloid-b peptides, b2-microglobulin,
and insulin (13,14). There are, however, conflicting reports
as to whether such inhibition is neuroprotective (15,16).
The sequence of aB-crystallin has amphipathic character,
and contains a hydrophobic N-terminal domain, a central
a-crystallin domain (common to all sHsps), and a hydrophilic
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and flexible 12-residue C-terminal extension (9). The amphipathic nature of the sequence is believed to be crucial to its
chaperone function, enabling aB-crystallin to bind to
exposed hydrophobic patches characteristic of misfolded
states (17). The hydrophilic and highly flexible C-terminal
extension, as characterized by solution state nuclear
magnetic resonance (NMR) (18), is also essential to efficient
chaperone activity, with an important role in solubilizing
complexes of the chaperone with misfolded and aggregated
species (10). No crystal structure of aB-crystallin has yet
been determined; comparison of the a-crystallin domain with
structures of other sHsps, however, suggests that the central
domain will adopt a b-sandwich structure (19). A major
barrier to structural characterization of aB-crystallin, and
certainly to its crystallization, is the self-association of
monomers into large, polydispersed assemblies (typically
24–33mers), with molecular masses varying from 300 kDa
to >1 MDa (20). Studies of the quaternary structure of the
protein by cryo-electron microscopy reveal spherical assemblies between 8 and 18 nm in diameter with a central cavity
(21), which undergo subunit exchange on a timescale of
minutes (22). This exchange is inhibited by binding to large
denatured or partially unfolded proteins, suggesting that
subunit exchange may have an important role in the mechanism of chaperone action (10,22).
aB-Crystallin accumulates in neurons and glia of the
central nervous system under pathological conditions (23),
becoming colocalized with aSyn in Lewy bodies along with
a host of other proteins including the sHsp Hsp27, and other
chaperones such as clusterin, Hsp70, and Hsp90 (24).
In vitro biophysical studies demonstrated complete inhibition
of the nucleated assembly of aSyn into fibrils by 0.25 equivalents of aB-crystallin (25). Imaging studies of the aggregation products showed large amounts of amorphous material,
which was interpreted as the binding of aB-crystallin to
monomeric or oligomeric intermediates, inhibiting the nucleation of fibrillar aSyn aggregates. Later studies additionally
demonstrated that the addition of 0.5 equivalents of aB-crystallin to aggregating samples of aSyn is highly effective in inhibiting further growth, and this was also interpreted as
a consequence of the stabilization of monomeric or prefibrillar
aSyn, inhibiting its incorporation into the growing fibril (26).
Given the complex mechanisms of amyloid formation and
the number of aggregated species involved—e.g., monomers,
oligomers, protofibrils, fibrils, and amorphous assemblies—
we were motivated to consider the interaction of aB-crystallin with additional species along the aggregation pathway
and, in particular, with the mature fibrils themselves, which
hitherto have largely been regarded as inert reaction products.
There is evidence, however, that this view might not be
correct, as aB-crystallin has been reported to bind to Ab40
fibrils, and it has been suggested that this interaction may
inhibit further aggregation (13), although the experimental
data reported could not conclusively distinguish between
the effects of the chaperone in solution or bound to the fibril.
Biophysical Journal 98(5) 843–851
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A separate study of insulin aggregation at low pH demonstrated that fibril elongation is inhibited after the incubation
of the insulin fibrils with aB-crystallin, where the detection
of binding stimulated the proposal that the latter serves to
limit further fibril growth (14). Here we investigate the
hypothesis that aB-crystallin might bind to aSyn fibrils,
and use a variety of techniques including newly developed
QCM and NMR methodologies to explore the range of
effects that result from such chaperone-fibril interactions.
MATERIALS AND METHODS
These are described in the Supporting Material.

RESULTS
Characterization of aSyn interactions
with aB-crystallin
The cosedimentation of aB-crystallin and two control
proteins (green fluorescent protein, GFP, and ubiquitin
hydrolase, UCH-L3) with preformed A53T aSyn fibrils
was assayed by SDS-PAGE (Fig. 1 A). A53T aSyn was
chosen for this study because of its high aggregation propensity relative to the WT protein (4), and it was found to pellet
aB-crystallin in a similar manner to that previously observed
for the WT (25). The intensity of staining with Coomassie
blue was used to estimate the amount of aB-crystallin
present in the pelleted fraction (Fig. S1 A in the Supporting
Material), and an approximate binding ratio of 0.6:1 aBcrystallin:aSyn was determined, where the latter refers to
the concentration of the constituent monomers within the
fibrils and the observed staining intensity was normalized
by protein mass. The corresponding binding ratios for GFP
and UCH-L3 were 0.1:1 and 0.01:1, respectively, both
consistent with residual material expected from the incomplete washing of the pellet, and indicating that the sedimentation of aB-crystallin was not due to any generic affinity of
proteins for hydrophobic patches on the fibril surface, or
rheological effects from the fibril network during centrifugation. aB-Crystallin alone was not observed to sediment
under these conditions (Fig. S1, B and C).
The intrinsic tryptophan fluorescence of aB-crystallin was
used to estimate the concentration of the protein remaining in
solution after incubation with preformed A53T fibrils and
centrifugation for 30 min at 16,000  g (Fig. 1 B); these
conditions were found sufficient to pellet aSyn fibrils
completely, and as aSyn does not contain any tryptophan
residues, it exhibits little intrinsic fluorescence. Only a small
(6%) though reproducible enhancement of aB-crystallin
fluorescence was detected in the presence of monomeric
aSyn (Fig. 1 B), with a concomitant blue-shift of 1 nm
(343–342 nm) indicative of the fluorophore being in a
more hydrophobic environment, and consistent with the
existence of a weak interaction between aB-crystallin and
monomeric aSyn (25).
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FIGURE 1 Characterization of interactions between aB-crystallin and
aSyn. (A) SDS-PAGE assay of the binding of aB-crystallin, GFP, and
UCH-L3 (all 50 mM) to aSyn fibrils (70 mM), showing both soluble fractions, S, and pelleted fractions, P, after centrifugation for 30 min at
16,000  g. (B) Intrinsic fluorescence of solutions containing aB-crystallin
(35 mM) and/or aSyn monomer (35 mM). The spectrum of aSyn monomer
alone has also been subtracted from that of aB-crystallin þ aSyn to illustrate
the 6% enhancement of aB-crystallin fluorescence observed in the presence
of aSyn ([aB þ aS] – aS). Additionally, a spectrum of aB-crystallin
remaining in solution after centrifugation with 0.5 equivalence of aSyn
fibrils is presented (aB þ aSFib).

To investigate its putative interaction with monomeric
aSyn further, aB-crystallin was titrated into uniformly
15
N-labeled aSyn, and changes in the amide chemical shifts
were monitored by recording [1H,15N]-HSQC experiments
(Fig. S2). Few significant changes were observed, and the
largest perturbation, at His50, can be attributed to its high
sensitivity to small changes in pH, an observation noted
previously in titrations of monomeric aSyn (8). A small,
uniform increase in signal intensity was observed, in contrast
to previous reports of a uniform loss of intensity (25). This
finding suggests that these changes are more probably attributable to the effect of slight pH changes on amide exchange
broadening than to the association of aSyn and aB-crystallin. Thus, whereas measurements of tryptophan fluorescence
imply that some interaction exists between the proteins, the
NMR results reported both here and previously (25) together
suggest that this is only transient and of low affinity, similar
perhaps to that characterized between aB-crystallin and the

amyloid-b peptide (27). For these reasons, these interactions
have not been explored further in this work.
The fluorescence assay was then used to measure the
concentration of aB-crystallin remaining in solution after
precipitation by the addition of aSyn fibrils at two concentrations. A precise determination of the stoichiometry or affinity
of the interaction between the sHsp and fibrils is complicated
by the effect of the interaction of aSyn monomer with
aB-crystallin, as discussed above, and Rayleigh scattering
resulting from the small number of aSyn fibrils that remain
in solution after centrifugation. In addition, allowance had
to be made for the effect of aB-crystallin on the monomerfibril equilibrium (discussed later) and hence on the absolute
fibril concentration. For these reasons, an exact analysis has
not been attempted, but it was observed that binding is
proportional to the fibril concentration, and an approximate
ratio of 0.23 5 0.06 bound aB-crystallin monomers per
aSyn monomer was calculated. This value is expected to
be a lower bound, with an absolute uncertainty greater
than the quoted standard deviation of the observations,
because of the factors discussed above. It is, however, of a
comparable order of magnitude to that estimated by densitometry (Fig. S1 A).
The binding ratios determined above may be restated in
terms of the available fibril surface area, using a toy model
(described in Materials and Methods; see Supporting Material) in which the aB-crystallin-fibril interaction is approximated as hard spheres of aB-crystallin monomers packing
onto a cylindrical fibril surface. Although there is evidence
that the active subunits of aB-crystallin may be dimeric
(28), provided that both monomers within any such dimers
interact with the fibril surface, we expect that this simple
model of monomeric binding will remain approximately
applicable. Such an analysis determines an approximate
maximum binding ratio of 0.90 5 0.29 aB-crystallin monomers per aSyn monomer, hence the values determined by
fluorescence and densitometry correspond to surface coverages of approximately 26 5 11% and 62 5 20%, respectively. Such high values require that the chaperone must
bind to the overall surface of the aSyn fibrils, and not just
to the small number of fibril ends.
Inhibition of ﬁbril elongation observed
by in situ ThT ﬂuorescence
Previous studies have examined the effect of aB-crystallin
on the sigmoidal kinetics characteristic of nucleated polymerization (and fragmentation) reactions associated with
the conversion of aSyn into amyloid fibrils (25,26). Such
reactions are typically highly stochastic, however, and their
quantitative interpretation in terms of individual microscopic
processes and rates is complex (7). To simplify the kinetic
analysis in this work, preformed fibrils were used to seed
the aggregation reaction in order that the elongation step
alone could be examined. A series of seeded aggregation
Biophysical Journal 98(5) 843–851
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experiments were performed in which the initial elongation
velocities were determined as a function of the concentration
of aB-crystallin (Fig. 2 A). These data show clearly that fibril
growth was inhibited at low micromolar concentrations of
aB-crystallin. Fitting to a sigmoidal dose-response curve
determined the IC50 (the concentration of aB-crystallin for
half-maximal inhibition) to be 335 5 86 nM, although
some dependence on the seed concentration may also be discerned, which shall be discussed later in this article.
To identify whether or not the inhibition observed above
resulted from the binding of chaperone to aSyn in fibrils
or free in solution, fibrils were preincubated with aB-crystallin then pelleted, washed, resuspended, and used to seed
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FIGURE 2 Effect of aB-crystallin on aSyn aggregation kinetics. (A)
Determination of the effective aB-crystallin concentration required for inhibition of seeded fibril elongation in the presence of 35 mM aSyn monomer,
as a function of varying fibril mass, given as the % seed. Data were globally
fitted to a one-site binding model as described in Materials and Methods (see
Supporting Material). Initial rates have been normalized to aSyn elongation
in the absence of aB-crystallin. The marker (*) indicates the relative
inhibition resulting from the preincubation of the fibril seed with aB-crystallin, observed in Fig. 2 B, given that the estimated residual concentration of
aB-crystallin was <35 nM. (B) Seeded elongation kinetics, monitored by
in situ ThT fluorescence. Samples containing 70 mM aSyn fibrils and/or
70 mM aB-crystallin, as indicated in the legend, were pelleted, washed,
and resuspended, then used to seed fresh aSyn monomer (35 mM, 5% w/w
seed, 20 mM ThT).
Biophysical Journal 98(5) 843–851

solutions of monomeric aSyn. Fig. 2 B plots the resultant
kinetic profiles, and shows that elongation of chaperonebound fibrils was significantly inhibited (~70-fold) relative
to untreated fibrils, by analysis of the initial rates. The
residual concentration of aB-crystallin after pelleting and
washing was estimated to be %35 nM. This is an order-ofmagnitude below the IC50 and therefore not by itself sufficient to inhibit elongation, as indicated by the marker in
Fig. 2 A. We therefore conclude that the observed inhibition
of elongation results from the specific interaction of aBcrystallin with the aSyn seed fibrils.
Inhibition of ﬁbril elongation observed
with a quartz crystal microbalance
To verify the model of inhibition discussed above, an independent technique utilizing a quartz crystal microbalance
(QCM) was employed. QCM is a technique in which the
mass deposited on the surface of a quartz crystal oscillator
may be determined directly via measurement of the
frequency of oscillation, and recently the method has been
applied to the study of amyloid growth by measuring the
change in mass of growing fibrils attached to the surface
(14). Importantly, this technique enables us to examine the
elongation phase of fibril growth in isolation to other
processes such as nucleation, and this has been used to determine the elongation kinetics of insulin fibrils grown at low
pH, demonstrating the inhibition of their elongation by
aB-crystallin (14). In contrast to insulin fibrils, aSyn fibrils
did not adsorb directly onto the sensor surface, and instead
were covalently attached via lysine side chains, as described
in Materials and Methods (see Supporting Material). A
surface prepared in this manner is shown in Fig. 3 A, and
the fibrils were observed to reproducibly elongate when
incubated with monomeric aSyn (Fig. 3 B). Elongation
was readily determined to be proportional to the monomer
concentration (Fig. S3), as previously observed by solutionstate measurements (6), implying that the presence of the surface does not significantly alter the elongation mechanism.
Fig. 3 C plots the change in deposited mass during a single
QCM experiment. This shows firstly the increase in mass
that results from the elongation of aSyn fibrils in the presence of aSyn monomer (arrow 1). The subsequent injection
of aB-crystallin with aSyn monomer (arrow 2) resulted in
a large increase in mass indicative of a binding interaction.
After 10 min, the reaction chamber was washed thoroughly
with buffer to eliminate unbound chaperone, yet upon the
injection of fresh aSyn monomer (arrow 3), further elongation was inhibited approximately sevenfold. As no free
aB-crystallin remained in solution, inhibition must have
resulted from the persistent binding of the chaperone to
fibrils, providing strong support for the solution-state inhibition results presented previously in Fig. 2.
A second experiment (Fig. 3 D) confirmed this observation: on injection of aSyn and aB-crystallin, a large initial
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FIGURE 3 Measurement of fibril elongation by QCM.
AFM imaging of the (A) preparation and (B) growth of
aSyn fibrils on an activated gold surface. (C) The effect
of aB-crystallin on fibril elongation, studied by QCM.
Mass loading plot showing mass changes calculated from
the (a) third, (b) fifth, and (c) seventh harmonics of the
crystal. Arrows indicate injection of 1), 0.25 mg/mL
A53T; 2), 0.25 mg/mL A53T plus 0.18 mg/mL aB-crystallin; and 3), 0.25 mg/mL A53T, showing approximately
sevenfold inhibition of elongation. (D) Elongation rates
determined in a separate QCM experiment, where aSyn
monomer was injected at 0.1 mg/mL in the absence or presence of aB-crystallin at 0.5 mg/mL, as labeled on the x axis.
The reaction chamber was flushed with fresh buffer
between measurements. As in Fig. 3 C, on injection of
aB-crystallin and aSyn, a large increase in mass loading
occurred over ~0.5 h, after which linear growth was
observed, and the elongation rate is plotted for this
steady-state condition. The final measurement of elongation was performed after overnight incubation of the
surface in fresh buffer.
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increase in mass loading was detected. In contrast to the
previous experiment, this binding was allowed to saturate,
and after ~30 min a small but constant elongation rate was
observed. It is perhaps noteworthy that this timescale for
association is of similar magnitude to that for the subunit
exchange of aB-crystallin (22), and may indicate that the
aB-crystallin subunits are the active chaperone species.
Again, the observed inhibition persisted when the reaction
chamber was flushed with fresh buffer. After overnight incubation of the crystallin-treated fibrils in fresh buffer,
however, the ability of the fibrils to elongate was partially
restored, thus demonstrating the reversibility of the fibrilcrystallin interaction. But the results also imply that dissociation of the complex occurs only on a timescale of several
hours, which is suggestive of a tight binding interaction.
NMR investigations of the interaction
of aB-crystallin with aSyn ﬁbrils
Large species such as amyloid fibrils, with masses of approximately GDa, have traditionally been assumed to be beyond
the reach of solution-state NMR methods. Recent investigations have demonstrated, however, that in some cases noncore
regions of fibrils have sufficient flexibility to allow us to detect
sharp resonances (29). Therefore, in a one-dimensional 1H
NMR spectrum of aB-crystallin in the presence of aSyn
fibrils, there are four components that may potentially
be observed: fibrillar aSyn; residual aSyn monomers;
monomeric/oligomeric aB-crystallin; and fibril-bound aBcrystallin. Residual monomeric species are key observables
in the study of the thermodynamics of polymerization, and
measurements designed to estimate this concentration have
been used to characterize the energetics of elongation for

several fibril-forming systems (30). The 1H spectrum of
aB-crystallin has previously been characterized, and reveals
that in the native oligomeric complex, the final 12 residues
in the C-terminal extension have sufficient mobility to be
observable by solution-state NMR (18).
Before examination of the fibril-chaperone complex, the
spectrum of aSyn fibrils in solution was explored. Fig. 4 A
shows a portion of the one-dimensional 1H NMR spectrum
of a solution of aSyn fibrils (green line). The fibril spectrum
appears almost identical to that of monomeric aSyn (not
shown), albeit with significantly reduced intensity. Although
this spectrum suggests that the bulk of the observed signal
arises from residual monomers in solution rather than the
fibrils, a more detailed study was nevertheless carried out
using a series of pulsed-field gradient (PFG) measurements
to define the effective diffusion coefficient Deff of the species
giving rise to the resonances. For monomeric proteins, Deff
is identical to the translational diffusion coefficient Dtrans,
and its value is independent of the diffusion delay in the
NMR experiment, D. By contrast, for very large molecular
assemblies such as amyloid fibrils, Deff can include contributions from rotational diffusion such that Deff > Dtrans for
small values of D (31). Deff is shown in Fig. S4 as a function
of D for a solution containing aSyn fibrils, and no such variation was detected. The mean value of Deff was 8.6(5 1.7) 
1011 m2 s1, which is entirely consistent with that expected
for a small monomeric protein (32). Thus, in contrast to other
amyloid systems such as the SH3 dimer, for which fibril
resonances are observable (29), the NMR signal in Fig. 4 A
may be attributed to residual aSyn monomers alone.
Having examined the spectrum of isolated aSyn fibrils (in
equilibrium with residual monomer), it is then possible to
analyze their interaction with aB-crystallin. Fig. 4 A shows
Biophysical Journal 98(5) 843–851
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FIGURE 4 Interaction of aB-crystallin with aSyn fibrils observed by onedimensional 1H NMR spectroscopy. (A) Methyl and DSS (resonance at
0 ppm) regions of the one-dimensional 1H spectra of 70 mM A53T aSyn
fibrils complexed with 20 mM aB-crystallin, and of the fibrils and chaperone
separately. (B) Effective diffusion coefficients determined for these samples
by PFG NMR experiments using a 500-ms diffusion delay.

the methyl region of the one-dimensional 1H NMR spectrum
of the fibril-crystallin complex alongside spectra of each
component in isolation. Difference spectroscopy, normalized
using the internal DSS reference, reveals that the spectrum
of chaperone-bound fibrils is not the sum of the original
components, but that there is additional signal in the spectrum of the complex. The difference spectrum had, however,
the same appearance as monomeric aSyn (Fig. 4 A). A comparison of intensities in repeated experiments using independent fibril samples determined that the mean aSyn intensity
in the presence of aB-crystallin is ~50% greater than that in
its absence.
To investigate these results further, PFG NMR spectra were
recorded to characterize the diffusion properties of the
observed resonances. To limit the contributions from rotational motion to the diffusion coefficients measured for
fibril-associated species, a long (500-ms) diffusion period D
was employed (31). The effective diffusion coefficients Deff
for each sample are plotted in Fig. 4 B and these data show
Biophysical Journal 98(5) 843–851

that the diffusion of aB-crystallin is retarded in the presence
of aSyn fibrils, consistent with the formation of a fibrilchaperone complex. The measured diffusion coefficients
correspond, according to the Stokes-Einstein relation, to
approximate hydrodynamic radii of 3.7 5 0.4 nm and 8.6 5
0.4 nm for free aSyn and aB-crystallin, respectively—in
good agreement with previous observations (21,33). The
effective diffusion coefficient of aB-crystallin in the presence
of aSyn fibrils corresponds, when modeled as rotating rigid
rods (31), to a mean fibril length of 260 5 140 nm.
The simplest interpretation of these results is that the
C-terminal extension of aB-crystallin is not perturbed by
fibril binding and remains free to tumble in solution; hence,
the one-dimensional NMR spectrum is not altered in the
presence of fibrils. However, diffusion is retarded, a finding
consistent with the binding of aB-crystallin to the fibrils. The
concentration of residual aSyn monomer is also increased in
the presence of aB-crystallin, indicating that the monomerfibril equilibrium is perturbed by interactions with the chaperone. Although absolute concentrations of aSyn monomer
were not determined, the observed 50% increase in the
monomer concentration corresponds to a net destabilization
of 0.3 5 0.1 kcal mol1 in the free energy of fibril elongation, assuming a simple polymerization model (30). It is
recognizable that the chaperone-monomer-fibril system
comprises many coupled equilibria, and that there are potentially multiple origins to the observed increase in monomer
concentration. It remains, however, a notable feature of polymerization reactions that a relatively small change in the net
elongation energy may still result in a large change in the
partition of monomers and fibrils.
Imaging of the ﬁbril-chaperone complex
To confirm the binding of aB-crystallin to aSyn fibrils in
a more direct manner, immunoelectron microscopy was
employed to visualize the fibril-crystallin complex. aSyn
fibrils are of sufficient size that their twisted ultrastructure
could be observed clearly in the electron microscope after
negative staining with uranyl acetate (Fig. 5 A). In contrast,
the aB-crystallin oligomers are more difficult to distinguish,
particularly in a multicomponent system. Samples were therefore incubated with an antibody directed against aB-crystallin, which was in turn stained with a secondary antibody
conjugated to 10-nm gold nanoparticles. Fig. 5 B shows a
sample of aB-crystallin prepared in this manner and negatively stained with uranyl acetate; electron dense gold
nanoparticles are observed to be colocalized with the native
aB-crystallin assemblies. The aSyn fibrils shown in Fig. 5 A
were also stained with the primary and secondary antibodies
by an identical protocol; no significant nonspecific or background immunolabeling was observed. An immunolabeled
fibril-crystallin complex containing 0.3 equivalents of aBcrystallin was then imaged (Fig. 5 C), showing, very clearly,
the interaction of aB-crystallin along the length of the fibrils,
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with gold nanoparticles observed on all faces of the fibril
surface including occasional binding at the fibril ends.
DISCUSSION
The results of this article have enabled a novel mechanism to
be proposed for the inhibition of aSyn aggregation by the
small heat-shock protein aB-crystallin. aB-Crystallin has
been demonstrated to bind along the lateral surface of
aSyn amyloid fibrils, and this interaction has been demonstrated by a range of methods to inhibit elongation effectively, with half-maximal inhibition at an aB-crystallin
concentration of 335 5 86 nM. Although the binding
epitopes of aB-crystallin and the fibrils are unknown,
NMR investigations have determined that the C-terminal
extension of aB-crystallin is able to fluctuate freely even
in the bound state, a finding consistent with its purported
role as a solubilizing domain (18). NMR measurements
also indicated that the presence of the chaperone perturbed
the monomer-fibril equilibrium, consistent with a net destabilization of the fibrils by ~0.3 kcal mol1. This may indicate
that binding of aB-crystallin along aSyn fibrils weakens the
interactions between adjacent aSyn molecules, similar to the
effect of cofilin binding to actin filaments (34), but the additional effect of a weak interaction between aB-crystallin and
monomeric aSyn cannot be ruled out at this stage.
In this work, a novel methodology based on QCM
measurements has been developed to monitor aSyn fibril
elongation, in isolation from other processes such as nucleation, and without the need for added probe molecules. As
has been demonstrated in studies of insulin aggregation
(14), this technique offers significant promise for the quantitative investigation of the kinetics and mechanism of aSyn
fibril elongation. To apply this, however, methods were
developed similar to those used in surface plasmon resonance to enable the gold surface to bind the fibrils. This
approach is likely to be applicable to QCM measurements
of other amyloid systems that do not contain accessible thiols
or disulphides.
aB-Crystallin has previously been reported to inhibit
aSyn aggregation, when added even at the midpoint of
sigmoidal assembly curves, and it was hypothesized that
the chaperone acts by stabilizing monomeric or prefibrillar
species (25,26). The mechanism put forward in this study,
by which aB-crystallin could inhibit fibril formation by
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FIGURE 5 Immunoelectron microscopy of aB-crystallin-aSyn fibril complexes. aB-Crystallin was labeled with
10-nm gold nanoparticles (arrows) as
described in Materials and Methods
(see Supporting Material). (A) aSyn
fibrils alone; (B) aB-crystallin alone;
and (C) aSyn fibrils plus 0.3 equivalence of aB-crystallin. All scale bars
are 500 nm.

binding to the fibrils and inhibiting their elongation, suggests
that there may be multiple mechanisms of chaperone action.
As binding is likely to occur at least in part to the hydrophobic clusters that may form in the fibrils, it is likely that
aB-crystallin will also interact strongly with the oligomeric
precursor species, an important property given their cytotoxic nature (2).
Two mechanisms can be envisaged to rationalize the inhibition of elongation that results from the interaction of aSyn
fibrils with aB-crystallin: one is a specific capping interaction of aB-crystallin with the fibril ends, assuming that the
binding here is tighter than that along the length of the fibril;
and the second involves uniform binding of aB-crystallin
along the length of the fibril, where inhibition results from
the chance occlusion of the fibril ends. In this latter binding
and occlusion model, inhibition is expected to be observed
only in the presence of near equimolar ratios of aB-crystallin
and aSyn fibrils, and the dependence of the IC50 upon the
seed concentration noted in Fig. 2 A would be consistent
with such a mechanism. Further investigations of the stoichiometry and affinity of the fibril-chaperone interaction will,
however, be required to differentiate these models with
confidence.
A key question in the study of sHsps is whether the native
oligomers act as chaperones directly, or whether dissociation
into subunits occurs before their binding (35). The approximate binding ratios presented in this work would be consistent with either a relatively uniform binding of monomeric or
dimeric aB-crystallin subunits along the fibril surfaces, or a
rarer binding of the oligomers. The high surface coverage
that would result from the subunit binding appears attractive
as a means of explaining the efficacy of inhibition, particularly as this effect persists when the chaperone is removed
from the solution after binding has occurred. Although this
mechanism of inhibition has not been put forward previously, it is consistent with previous studies in which sHsp
subunit exchange dynamics have been correlated to chaperone activity, in both aB-crystallin and its phosphorylated
derivatives (22,36).
These findings present the suggestion that other sHsps
may act by a similar mechanism. The Hsp20 from the bovine
parasite Babesia bovis inhibits Ab40 amyloid formation,
and the chaperone was active only at low (10–100 nM)
concentrations in which dimeric subunits were prevalent,
whereas at higher chaperone concentrations, in which larger
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oligomers became populated, the inhibition of aggregation
was no longer observed (37). Additionally, aB-crystallin may
bind to components of the cytoskeleton including intermediate filaments and microtubules, although electron
microscopy has demonstrated that such binding occurs via
the oligomeric complex rather than isolated subunits (38).
This suggests that different chaperone activities (e.g., suppressing amyloid formation, thermally induced amorphous
aggregation, and cytoskeletal binding) correspond to a variety
of phosphorylation or oligomerization states and binding
modes. For example, lysozyme unfolding intermediates are
bound by multimeric Hsp27 (39), and whereas aB-crystallin
activity against aSyn amyloid formation increases with
temperature (correlating with increased subunit exchange),
little variation with temperature was observed against the
thermally induced amorphous aggregation of alcohol dehydrogenase and citrate synthase (40). Phosphorylationmimicking mutations have also been demonstrated to differentially regulate the chaperone activity of aB-crystallin
against amyloid fibril formation and amorphous aggregation
(36). Equally, however, some of this variation may result
from a degree of specificity of individual members of the
sHsp family (41).
aB-Crystallin has shown no evidence of ATPase or
refolding activity (19). Instead, sHsps have been proposed
to bind to misfolded states before interaction with other
chaperone systems, which may facilitate refolding or degradation (41). Horwitz et al. (9) has suggested that aB-crystallin in the eye lens may act as an irreversible sink for unfolded
or misfolded proteins, as there is no evidence of further chaperone systems within the lens, and active protein synthesis
does not occur once the lens proteins are laid down. The
binding of aB-crystallin to aSyn fibrils may therefore be a
protective mechanism to stem the growth of amyloid
deposits before clearance by further quality control mechanisms within the cell (41). This hypothesis is supported
by a mouse model of PD expressing A53T aSyn, in which
selective upregulation of aB-crystallin was observed in
affected glial cells (42). Additionally, we suggest that
binding of aB-crystallin to fibrils may reduce their cytotoxicity by camouflaging exposed hydrophobic surfaces. This
hypothesis is supported by a tissue culture model of Lewy
body disease in which colocalization of aB-crystallin with
aSyn deposits occurs without a reduction in the number of
inclusions compared to cells not transfected with aB-crystallin, although there is a significant reduction in cytotoxicity
(43). Finally, as exposed fibril surfaces have been proposed
to act as sites of secondary fibril nucleation (44), the coating
of aSyn fibrils by aB-crystallin could inhibit not just their
elongation but further nucleation processes as well. It is
also possible, however, that fibril binding by chaperones
may have a deleterious role by sequestering them and
reducing their efficacy in other physiological functions,
e.g., interacting with misfolded monomers or oligomers,
or, indeed, helping in regulation of the cytoskeleton (41).
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Certainly, these findings reveal novel activities of the cellular
proteostasis network, which is of growing interest in the
field of systems biology, and an increasing understanding
of its behavior may contribute to the rational development
of therapeutic proteostasis regulators (45).
This finding is also likely to have general relevance to
other amyloid and chaperone systems. Indeed, recent work
suggests that another chaperone, Hsp104, is capable of suppressing amyloid growth at many stages along the aggregation pathway, including the elongation of mature fibrils (46).
Fibril binding and inhibition of elongation by aB-crystallin
has previously been demonstrated for the Ab40 peptide,
although no causal link was demonstrated (13). Inhibition
of b2-microglobulin elongation by aB-crystallin at low pH
was also reported (13), and inhibition of insulin aggregation under similar conditions has also been observed (14).
This work is therefore important in extending mechanistic
studies of aB-crystallin to physiological conditions and,
given apparent similarities in the behavior of aSyn, Ab40,
b2-microglobulin, and insulin, suggests a generic mechanism
of aB-crystallin action.
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